BACKGROUND: @entity3 ( @entity3 ) are a rare occurrence in well-differentiated @entity259 . The aim of this study was to analyze the clinical, pathologic, and molecular features of primary @entity259 with low-risk histology that develop @entity3 . METHODS: A detailed clinicopathologic review and targeted next-generation sequencing were performed on a cohort of well-differentiated @entity259 lacking gross extrathyroidal extension, extensive @entity1350 , or significant lymph node @entity3 but exhibiting @entity3 . RESULTS: Primary well-differentiated @entity259 with low-risk histologic features and @entity3 was a rare occurrence, accounting for only 3% of metastatic non-anaplastic @entity259 . All 15 cases meeting the inclusion criteria harbored @entity3 at presentation. The majority (11/15) of these @entity5 were follicular variant of @entity3557 ( @entity3557 ), especially the encapsulated form (n   =   8). The remaining @entity1 harbored encapsulated H  rthle cell @entity189 (n   =   2), encapsulated @entity189 (n   =   1), and an encapsulated @entity1377 classical variant (n   =   1). Of the 12 encapsulated @entity189 , 10 had capsular invasion only and no @entity1350 . Ninety-two percent of the @entity5 exhibited extensive intra-tumoral @entity82 . Among the eight @entity5 that were subjected to next-generation sequencing analysis, a RAS mutation was the main driver (5/8), and @entity2215 promoter mutation was highly prevalent (6/8). In four cases, @entity2215 promoter mutations were associated with RAS or @entity817 mutations. @entity817 -mutated classical variant of @entity1377 also presented with @entity3 but was less common (1/8). In 11/15 cases, the clinician was able to diagnose distant disease based on the clinical presentation. In 3/4 incidental cases that were genotyped, @entity2215 promoter mutations were found. CONCLUSIONS: When @entity3 occur in primary @entity259 with low-risk histology, they are almost always found at presentation. The majority are encapsulated follicular variant of @entity3557 with capsular invasion only. @entity2215 promoter mutations occur at a higher rate than that seen in @entity3557 in general and may help explain the aggressive behavior of these histologically deceptive primary @entity189 .

Primary XXXX with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics.

@entity3557 :: ('MESH:C536915', 'Disease') :: ['papillary thyroid carcinoma', 'PTC'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity1377 :: ('MESH:D002291', 'Disease') :: ['papillary carcinoma'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis'] @entity2215 :: ('7015', 'Gene') :: ['TERT'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas', 'carcinoma', 'follicular carcinoma'] @entity1350 :: ('MESH:D019043', 'Disease') :: ['vascular invasion'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases', 'DM', 'Distant metastases'] @entity817 :: ('673', 'Gene') :: ['BRAF'] @entity259 :: ('MESH:D013964', 'Disease') :: ['thyroid carcinoma']
@entity259 :: (MESH:D013964,Disease) :: ['Thyroid Carcinoma']
